Sanofi SA (EPA:SAN) has been given a €83.00 ($98.81) price target by stock analysts at BNP Paribas in a research note issued on Wednesday. The brokerage currently has a “neutral” rating on the stock.

Other equities research analysts have also recently issued research reports about the company. Morgan Stanley set a €91.00 ($108.33) target price on Sanofi SA and gave the stock a “buy” rating in a report on Tuesday, June 6th. Credit Suisse Group set a €95.00 ($113.10) target price on Sanofi SA and gave the stock a “buy” rating in a report on Tuesday, July 4th. Kepler Capital Markets set a €89.00 ($105.95) target price on Sanofi SA and gave the stock a “buy” rating in a report on Wednesday, July 26th. Deutsche Bank AG set a €96.00 ($114.29) target price on Sanofi SA and gave the stock a “buy” rating in a report on Tuesday, August 1st. Finally, Goldman Sachs Group, Inc. (The) set a €82.00 ($97.62) target price on Sanofi SA and gave the stock a “neutral” rating in a report on Wednesday, July 26th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of €88.06 ($104.84).

Sanofi SA (SAN) traded up 0.34% during midday trading on Wednesday, hitting €82.21. The company had a trading volume of 1,674,653 shares. The stock has a market cap of €103.24 billion and a price-to-earnings ratio of 11.47. Sanofi SA has a 12-month low of €62.50 and a 12-month high of €92.97. The company’s 50 day moving average is €25.48 and its 200 day moving average is €25.74.

TRADEMARK VIOLATION WARNING: “Sanofi SA (SAN) Given a €83.00 Price Target at BNP Paribas” was posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/09/10/sanofi-sa-san-given-a-83-00-price-target-at-bnp-paribas.html.

Sanofi SA Company Profile

Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company operates in two segments, Pharmaceuticals and Vaccines. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Analyst Recommendations for Sanofi SA (EPA:SAN)

Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.